Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden Featured Article: Tom W.C. Lung, Dennis Petrie, William.

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Incretin-Based Drugs and the Risk of Congestive Heart Failure Featured Article: Oriana Hoi Yun Yu, Kristian B. Filion, Laurent Azoulay, Valerie Patenaude,
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Interpreting Adverse Signals in Diabetes Drug Development Programs Featured Article: Clifford J. Bailey, Ph.D. Diabetes Care Volume 36: 1-9 July, 2013.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Vitamin D Levels Predict All-Cause and Cardiovascular Disease Mortality in Subjects With the Metabolic Syndrome Featured Article: G. Neil Thomas, Ph.D.,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Cystatin C– and Creatinine-Based Estimated Glomerular Filtration Rate, Vascular Disease, and Mortality in Persons With Diabetes in the U.S. Featured Article:
Clinical Outcomes with Newer Antihyperglycemic Agents
Microvascular Complications in Childhood- Onset Type 1 Diabetes and Celiac Disease: A Multicenter Longitudinal Analysis of 56,514 Patients From the German-Austrian.
Impact of Socioeconomic Status on Cardiovascular Disease and Mortality in 24,947 Individuals With Type 1 Diabetes Featured Article: Araz Rawshani, Ann-Marie.
Risk and Recurrence of Serious Adverse Outcomes in the First and Second Pregnancies of Women With Preexisting Diabetes Featured Article: Peter W.G. Tennant,
Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Risk of Dementia in Seniors with Newly Diagnosed Diabetes: A Population-Based Study Featured Article: Nisha Nigil Haroon, Peter C. Austin, Baiju R. Shah,
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Long-Term Complications and Mortality in Young-Onset Diabetes Type 2 diabetes is more hazardous and lethal than type 1 diabetes Featured Article: Maria.
Diabetes and Cause-Specific Mortality in a Prospective Cohort of One Million U.S. Adults Featured Article: Peter T. Campbell, Ph.D., Christina C. Newton,
4S: Scandinavian Simvastatin Survival Study
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes Featured Article:
Gestational Age and Birth Weight and the Risk of Childhood Type 1 Diabetes: A Population- Based Cohort and Sibling Design Study Featured Article: Ali S.
Mortality After Incident Cancer in People With and Without Type 2 Diabetes Featured Article: Craig J. Currie, Ph.D., Chris D. Poole, Ph.D., Sara Jenkins-Jones,
High Concentrations of AGE-LDL and Oxidized LDL in Circulating Immune Complexes Are Associated With Progression of Retinopathy in Type 1 Diabetes Featured.
Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes Featured Article: Sjoerd T. Nauta, M.S.C., Jaap W. Deckers,
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Loss of anterior forces (R waves) may signify prior anterior myocardial infarction. The aim of the present study was to determine the prevalence and prognostic.
The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.
Celiac Disease Increases Risk of Thyroid Disease in Patients With Type 1 Diabetes: A Nationwide Cohort Study Featured Article: Matthew Kurien, Kaziwe Mollazadegan,
Severe Hypoglycemia Identifies Vulnerable Patients With Type 2 Diabetes at Risk for Premature Death and All-Site Cancer: The Hong Kong Diabetes Registry.
Discontinuation of medication after nonfatal event: MI
The SPRINT Research Group
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:
LEADER trial: Primary Outcome
The IDEAL Study Reference
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
on behalf of the LEADER Trial Steering Committee and Investigators
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Relative risk of major events with atenolol vs placebo
Heart failure.
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Cumulative incidences of events, according to glucose-control strategy
Amit X. Garg, William F. Clark, R. Brian Haynes, Andrew A. House 
Pulse pressure for selecting the optimal cardiac strategy in patients with type 2 diabetes and coronary artery disease  Tetsuro Tsujimoto, Hiroshi Kajio 
Baseline Characteristics of the Subjects*
Collet JP, et al. Lancet 2009;373:309-17
Baseline Characteristics of the Patients – Part I
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )
EMPA-REG OUTCOME: Cumulative incidence of the primary outcome
Recurrent Vascular Access Dysfunction as a Novel Marker of Cardiovascular Outcome and Mortality in Hemodialysis Patients Kim et al. Am J Nephrol 2016;44:71-80.
A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:
Christian Madelaire et al. JCHF 2018;6:
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.
Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.
Cumulative mean numbers of confirmed (plasma glucose ≤3
Presentation transcript:

Severe Hypoglycemia and Mortality After Cardiovascular Events for Type 1 Diabetic Patients in Sweden Featured Article: Tom W.C. Lung, Dennis Petrie, William H. Herman, Andrew J. Palmer, Ann-Marie Svensson, Bjorn Eliasson, and Philip M. Clarke Diabetes Care Volume 37: November, 2014

STUDY OBJECTIVE To examine whether previous severe hypoglycemic events were associated with the risk of all-cause mortality after major cardiovascular events in type 1 patients Lung T. W.C. et al. Diabetes Care 2014;37:

STUDY DESIGN AND METHODS Data were from the Swedish National Diabetes Register Patients included those with type 1 diabetes who visited a clinic during 2002–2010 and experienced a major cardiovascular complication after the visit Two-part model was estimated for all-cause mortality after a cardiovascular event: 1.Logistic regression for death within the first month 2.Cox proportional hazards model conditional on 1- month survival 5-year cumulative mortality risk was estimated from the models for patients with and without prior diabetes complications Lung T. W.C. et al. Diabetes Care 2014;37:

RESULTS 1,839 patients experienced major cardiovascular events 403 had previously experienced severe hypoglycemic events 703 died within our study period A prior hypoglycemic event was associated with a significant increase in mortality after a cardiovascular event Patients with prior hypoglycemia had an estimated 5-year cumulative mortality risk of 52.4 and 39.8% for myocardial infarction and stroke, respectively Lung T. W.C. et al. Diabetes Care 2014;37:

CONCLUSIONS Patients with type 1 diabetes in Sweden with prior severe hypoglycemic events have increased risk of mortality after a cardiovascular event Lung T. W.C. et al. Diabetes Care 2014;37: